SCHEMBL17117574

SCHEMBL17117574

CC(C)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(N)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PREP P48147 3/20 0.46
▸ FAP Q12884 3/20 0.46
▸ ACE P12821 8/20 0.41
▸ REN P00797 4/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ F2 P00734 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ LTA4H P09960 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ PEPD P12955 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ PTGS1 P23219 1/20 0.41
▸ HTR2A P28223 1/20 0.41
▸ PTGS2 P35354 1/20 0.41
▸ HRH1 P35367 1/20 0.41
▸ THPO P40225 1/20 0.41
▸ PMP22 Q01453 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ ACE2 Q9BYF1 1/20 0.41
▸ DPP4 P27487 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18681013 0.96 PREP (0.42) PREPFAPACERENKDM4E
SCHEMBL18681193 0.91 PREP (0.38) PREPFAPACERENDPP4
SCHEMBL13402537 0.90 FAP (0.45) PREPFAPACERENKDM4E
SCHEMBL18681643 0.87 PREP (0.50) PREPFAPACERENKDM4E
SCHEMBL23314580 0.87 PREP (0.61) PREPFAPACERENKDM4E
SCHEMBL26616445 0.87 PREP (0.47) PREPFAPACERENKDM4E
SCHEMBL26616435 0.87 PREP (0.47) PREPFAPACERENKDM4E
SCHEMBL26616440 0.87 PREP (0.47) PREPFAPACERENKDM4E
SCHEMBL18681072 0.84 PREP (0.45) PREPFAPACERENKDM4E
SCHEMBL11516346 0.83 FKBP5 (0.44) PREPFAPACERENKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10392422-B2 Macrocyclic broad spectrum antibiotics RQX PHARMACEUTICALS, INC. (US) 2019-08-27 — — US disclosed
US-10351595-B2 — — 2019-07-16 — — US disclosed
US-20170088582-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS RQX PHARMACEUTICALS, INC. (US) 2017-03-30 — — US disclosed
EP-2010556-B1 HOMOGENEOUS ERYTHROPOIETIN AND METHOD FOR THEIR PREPARATION SLOAN KETTERING INST CANCER (US) 2015-09-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10351595-B2 — MRPL21, PRSS1, PEPD PREP 10/4885FAP 109/4885ACE 206/4885
US-10392422-B2 Macrocyclic broad spectrum antibiotics MRPL21, PEPD, CTSC PREP 16/4885FAP 206/4885ACE 170/4885
US-20170088582-A1 MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS MRPL21, PEPD, CTSC PREP 16/4885FAP 206/4885ACE 170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback